Entrada Therapeutics, Inc. (TRDA)

NASDAQ: TRDA · IEX Real-Time Price · USD
15.76
-0.05 (-0.32%)
Sep 30, 2022 4:00 PM EDT - Market closed
-0.32%
Market Cap 494.37M
Revenue (ttm) n/a
Net Income (ttm) -77.73M
Shares Out 31.37M
EPS (ttm) -4.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 60,335
Open 15.23
Previous Close 15.81
Day's Range 15.23 - 16.19
52-Week Range 5.12 - 36.85
Beta n/a
Analysts Buy
Price Target 13.26 (-15.9%)
Earnings Date Aug 11, 2022

About TRDA

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company w... [Read more...]

Industry Biotechnology
IPO Date Oct 29, 2021
Employees 122
Stock Exchange NASDAQ
Ticker Symbol TRDA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for TRDA stock is "Buy." The 12-month stock price forecast is 13.26, which is a decrease of -15.86% from the latest price.

Price Target
$13.26
(-15.86% downside)
Analyst Consensus: Buy
Stock Forecasts

News

Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

BOSTON, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape ...

1 month ago - GlobeNewsWire

Entrada Therapeutics Reports Second Quarter 2022 Financial Results

On track to submit Investigational New Drug application to the U.S. Food and Drug Administration for ENTR-601-44 targeting Duchenne muscular dystrophy in Q4 2022

1 month ago - GlobeNewsWire

Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer

BOSTON, July 19, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape ...

2 months ago - GlobeNewsWire

Entrada Therapeutics to Present at William Blair Biotech Focus Conference

BOSTON, July 06, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape ...

2 months ago - GlobeNewsWire

Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halted on Tuesday

We've seen a large array of halted stocks today as circuit breakers take effect to reign in unexpected volatility for some shares. The post Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halted ...

3 months ago - InvestorPlace

Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape ...

4 months ago - GlobeNewsWire

Entrada Therapeutics Reports First Quarter 2022 Financial Results

Second clinical candidate, ENTR-701, announced for the potential treatment of myotonic dystrophy type 1

4 months ago - GlobeNewsWire

Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle (EEV™) Therapeutic...

New non-human primate data demonstrate a durability of response through 12 weeks for lead clinical candidate, ENTR-601-44, for the potential treatment of Duchenne muscular dystrophy

4 months ago - GlobeNewsWire

Short Squeeze Stocks: ATER, NEGG and 3 Others Experts Think Are Ready to Pop

Short squeeze stocks are trending this morning following the release of Fintel's weekly short-squeeze ranking. Which companies are on top?

Other symbols: ATERNEGGBEEMCLVR
5 months ago - InvestorPlace

5 Short Squeeze Candidates To Watch: Aterian And Newegg Remain In Top Two Positions, Cannabis Company Joins List Week...

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

Other symbols: ATERNEGGBEEMCLVR
5 months ago - Benzinga

Entrada Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

On track to submit IND application for ENTR-601-44 targeting Duchenne muscular dystrophy in 2H 2022

6 months ago - GlobeNewsWire

Entrada Therapeutics to Participate in Cowen 42nd Annual Health Care Conference

BOSTON, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape ...

7 months ago - GlobeNewsWire

Entrada Therapeutics Announces the Appointment of Jared Cohen, PhD, JD to General Counsel

BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape ...

8 months ago - GlobeNewsWire

Entrada Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes

BOSTON, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape ...

9 months ago - GlobeNewsWire

Entrada Therapeutics Reports Third Quarter 2021 Financial Results

Successful completion of upsized $208.7 million Initial Public Offering

9 months ago - GlobeNewsWire

Entrada Therapeutics Announces Closing of Initial Public Offering

BOSTON, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients by establishing Endosomal Escape Vehicle (EEV™) the...

11 months ago - GlobeNewsWire

Entrada Therapeutics Announces Pricing of Upsized Initial Public Offering

BOSTON, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients by establishing Endosomal Escape Vehicle (EEV™) the...

11 months ago - GlobeNewsWire